Answers are grounded in this paper and cite their sources.
In recent years, a new promising application of adoptive cell therapy (ACT) has been enabled by the development of technologies and the successful clinical use of T cells with a chimeric antigen receptor (CAR-T) for treating patients with malignant B-cell neoplasms.In this study, we obtained CAR-T cells with the second-generation chimeric antigen receptor FMC63-28Z-CAR.The effectiveness of the obtained CAR-T cells against the monolayer of the modified PC-3M prostate carcinoma cell line (Kat + CD19 + ) was evaluated.A correlation was demonstrated between an increased secretion of the proinflammatory cytokines IFNγ, TNFα, IL6 and a decreased confluence of the tumor cells monolayer.At the same time, a pronounced antitumor effect of CAR-T cells was observed starting from day 5 of coincubation.Thus, the proposed approach can potentially be applied for a preliminary evaluation of the effectiveness of biomedical CAR-T cell products in the treatment of solid tumors.
No takes yet. Share an insight, caveat, or question.
Валиуллина et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: